miR-766-3p is also known as a dual player in cancer, it showed an anti-cancer effect on HCC by targeting WNT3A [262], but it is also known to inhibit cell-cycle progression and metastasis of RCC by targeting SF2 [263] and HCC by targeting MTA3 [284], respectively. Here, MTA3 is linked to cancer.